BERKELEY, CA 07/09/12 — Dynavax Technologies Corporation (DVAX) announced today that it plans to present at the 7th Annual JMP Securities Healthcare Conference in New York on Thursday, July 12, at 10:00 a.m. EDT (7:00 a.m. PDT).
Tyler Martin, M.D., President and Chief Medical Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax’s website athttp://investors.dynavax.com/newsevents.cfm.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company’s lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines. A U.S. BLA for HEPLISAV has been accepted for review by the FDA. For more information visitwww.dynavax.com.
